Literature DB >> 10471787

Lysophosphatidylcholine phosphorylates CREB and activates the jun2TRE site of c-jun promoter in vascular endothelial cells.

Y Ueno1, N Kume, S Miyamoto, M Morimoto, H Kataoka, H Ochi, E Nishi, H Moriwaki, M Minami, N Hashimoto, T Kita.   

Abstract

Lysophosphatidylcholine (lyso-PC), a polar phospholipid increased in atherogenic lipoproteins and atherosclerotic lesions, has been shown to induce transcription of a variety of endothelial genes relevant to atherogenesis. Lyso-PC has been shown to activate c-jun N-terminal kinase (JNK) and activator protein 1 (AP-1) and thereby stimulate transcription of the c-jun gene. Here we provide evidence that lyso-PC can phosphorylate cyclic AMP responsive element binding protein (CREB) and thereby activate the jun2 12-O-tetradecanoylphorbol 13-acetate response element (jun2TRE) site of the c-jun promoter, which appears to be the major molecular mechanism involved in lyso-PC-induced c-jun gene expression in cultured bovine aortic endothelial cells (BAEC). Transient transfection of BAEC with a 1.6-kbp c-jun promoter and luciferase reporter fusion gene resulted in a 12.9-fold increase in luciferase activity by lyso-PC treatment. Serial deletion mutation in c-jun promoter and luciferase reporter gene assay revealed that the 5' promoter region between nucleotide numbers -268 and -127, which contains a jun2TRE binding sequence, was most crucial for lyso-PC-induced transcription. The 5' promoter region between -76 and -27, which contains an AP-1 site, also affected lyso-PC-induced transcription of the c-jun gene. Point mutation in the jun2TRE site reduced lyso-PC-induced transcription of the c-jun promoter-luciferase fusion gene by a 70.3% decrease in c-jun promoter activity. Electrophoretic mobility shift assays showed increased binding of (32)P-labeled oligonucleotides with jun2TRE in nuclear extracts isolated from lyso-PC-treated BAEC, which was abolished or supershifted by anti-CREB antibody. Immunoblotting with anti-phosphorylated CREB antibody showed rapid phosphorylation of this protein after lyso-PC treatment. These results indicate that lyso-PC phosphorylates CREB, which was then bound to the jun2TRE site of the c-jun promoter and activated transcription. Activation of jun2TRE may play a key role in the transcriptional activation of c-jun as well as other endothelial genes depending upon these transcription factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471787     DOI: 10.1016/s0014-5793(99)01049-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Early differential elevation and persistence of phosphorylated cAMP-response element binding protein (p-CREB) in the central nervous system of hens treated with diisopropyl phosphorofluoridate, an OPIDN-causing compound.

Authors:  Tirupapuliyur V Damodaran; Ali A Abdel-Rahman; Hagir B Suliman; Mohamed B Abou-Donia
Journal:  Neurochem Res       Date:  2002-03       Impact factor: 3.996

3.  A phospholipidomic analysis of all defined human plasma lipoproteins.

Authors:  Monireh Dashti; Willem Kulik; Frans Hoek; Enno C Veerman; Maikel P Peppelenbosch; Farhad Rezaee
Journal:  Sci Rep       Date:  2011-11-07       Impact factor: 4.379

4.  A comprehensive pathway map of epidermal growth factor receptor signaling.

Authors:  Kanae Oda; Yukiko Matsuoka; Akira Funahashi; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2005-05-25       Impact factor: 11.429

Review 5.  A comprehensive map of the toll-like receptor signaling network.

Authors:  Kanae Oda; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2006-04-18       Impact factor: 11.429

6.  Stimulated bronchial epithelial cells release bioactive lysophosphatidylcholine 16:0, 18:0, and 18:1.

Authors:  Yan Zhuge; Yang Yuan; Richard van Breemen; Michael Degrand; Oksana Holian; Mark Yoder; Hazel Lum
Journal:  Allergy Asthma Immunol Res       Date:  2013-11-28       Impact factor: 5.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.